Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMGN Amgen	$336.79 +0.1%	$342.53	$267.83 ▼ $391.29	$181.60B	0.44	2.53 million shs	2.95 million shs
PFE Pfizer	$26.18 +0.2%	$26.77	$23.06 ▼ $28.75	$148.98B	0.35	33.36 million shs	48.26 million shs
TEVA Teva Pharmaceutical Industries	$35.32 +2.3%	$32.35	$14.99 ▼ $37.35	$39.69B	0.86	5.37 million shs	16.85 million shs
VTRS Viatris	$16.26 +0.9%	$14.92	$8.40 ▼ $17.53	$18.76B	0.88	12.55 million shs	16.93 million shs
VTRS Viatris	$16.26 +0.9%	$14.92	$8.40 ▼ $17.53	$18.76B	0.88	12.55 million shs	16.93 million shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMGN Amgen	+0.12%	-0.28%	-0.91%	-13.31%	+20.86%
PFE Pfizer	-0.32%	+0.89%	-1.10%	-5.26%	+12.83%
TEVA Teva Pharmaceutical Industries	-0.16%	+0.99%	+9.16%	+2.06%	+90.53%
VTRS Viatris	-1.10%	-2.13%	+8.70%	+7.90%	+87.54%
VTRS Viatris	-1.10%	-2.13%	+8.70%	+7.90%	+87.54%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMGN Amgen	$336.79 +0.1%	$342.53	$267.83 ▼ $391.29	$181.60B	0.44	2.53 million shs	2.95 million shs
PFE Pfizer	$26.18 +0.2%	$26.77	$23.06 ▼ $28.75	$148.98B	0.35	33.36 million shs	48.26 million shs
TEVA Teva Pharmaceutical Industries	$35.32 +2.3%	$32.35	$14.99 ▼ $37.35	$39.69B	0.86	5.37 million shs	16.85 million shs
VTRS Viatris	$16.26 +0.9%	$14.92	$8.40 ▼ $17.53	$18.76B	0.88	12.55 million shs	16.93 million shs
VTRS Viatris	$16.26 +0.9%	$14.92	$8.40 ▼ $17.53	$18.76B	0.88	12.55 million shs	16.93 million shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMGN Amgen	+0.12%	-0.28%	-0.91%	-13.31%	+20.86%
PFE Pfizer	-0.32%	+0.89%	-1.10%	-5.26%	+12.83%
TEVA Teva Pharmaceutical Industries	-0.16%	+0.99%	+9.16%	+2.06%	+90.53%
VTRS Viatris	-1.10%	-2.13%	+8.70%	+7.90%	+87.54%
VTRS Viatris	-1.10%	-2.13%	+8.70%	+7.90%	+87.54%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMGN Amgen	2.48	Hold	$355.19	5.46% Upside
PFE Pfizer	2.20	Hold	$28.82	10.08% Upside
TEVA Teva Pharmaceutical Industries	2.80	Moderate Buy	$41.78	18.27% Upside
VTRS Viatris	2.38	Hold	$16.43	1.04% Upside
VTRS Viatris	2.38	Hold	$16.43	1.04% Upside

Current Analyst Ratings Breakdown

Latest TEVA, VTRS, PFE, AMGN, and VTRS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/27/2026	PFE Pfizer	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral	$27.00
5/20/2026	AMGN Amgen	Argus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$400.00 ➝ $375.00
5/19/2026	VTRS Viatris	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$17.00 ➝ $22.00
5/19/2026	VTRS Viatris	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$17.00 ➝ $22.00
5/14/2026	PFE Pfizer	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Underperform	$26.00
5/14/2026	AMGN Amgen	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$432.00 ➝ $427.00
5/13/2026	AMGN Amgen	Daiwa Securities Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$410.00 ➝ $390.00
5/8/2026	VTRS Viatris	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D) ➝ Sell (D+)
5/8/2026	VTRS Viatris	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D) ➝ Sell (D+)
5/8/2026	VTRS Viatris	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$18.00 ➝ $20.00
5/8/2026	VTRS Viatris	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$18.00 ➝ $20.00

(Data available from 5/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMGN Amgen	$36.75B	4.95	$33.85 per share	9.95	$17.03 per share	19.78
PFE Pfizer	$62.58B	2.38	$4.40 per share	5.95	$15.86 per share	1.65
TEVA Teva Pharmaceutical Industries	$17.35B	2.34	$3.82 per share	9.25	$7.16 per share	4.93
VTRS Viatris	$14.30B	1.32	$7.46 per share	2.18	$12.59 per share	1.29
VTRS Viatris	$14.30B	1.32	$7.46 per share	2.18	$12.59 per share	1.29

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMGN Amgen	$7.71B	$14.37	23.44	14.29	3.38	20.96%	137.41%	13.28%	8/4/2026 (Estimated)
PFE Pfizer	$7.77B	$1.31	19.99	9.15	N/A	11.83%	19.44%	8.41%	8/4/2026 (Estimated)
TEVA Teva Pharmaceutical Industries	$1.41B	$1.33	26.56	11.62	3.34	9.01%	43.53%	8.19%	7/29/2026 (Estimated)
VTRS Viatris	-$3.51B	-$0.26	N/A	6.02	1.42	-2.04%	19.04%	7.62%	8/6/2026 (Estimated)
VTRS Viatris	-$3.51B	-$0.26	N/A	6.02	1.42	-2.04%	19.04%	7.62%	8/6/2026 (Estimated)

Latest TEVA, VTRS, PFE, AMGN, and VTRS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/7/2026	Q1 2026	VTRS Viatris	$0.52	$0.59	+$0.07	$0.15	$3.36 billion	$3.52 billion
5/7/2026	Q1 2026	VTRS Viatris	$0.52	$0.59	+$0.07	$0.15	$3.36 billion	$3.52 billion
5/5/2026	Q1 2026	PFE Pfizer	$0.7220	$0.75	+$0.0280	$0.47	$13.84 billion	$14.45 billion
4/30/2026	Q1 2026	AMGN Amgen	$4.77	$5.15	+$0.38	$3.34	$8.58 billion	$8.62 billion
4/29/2026	Q1 2026	TEVA Teva Pharmaceutical Industries	$0.50	$0.53	+$0.03	$0.31	$3.79 billion	$3.98 billion
3/31/2026	Q1 2026	TEVA Teva Pharmaceutical Industries	N/A	$0.53	N/A	$0.31	N/A	$3.98 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMGN Amgen	$10.08	2.99%	+8.27%	70.15%	14 Years
PFE Pfizer	$1.72	6.57%	-13.20%	131.30%	16 Years
TEVA Teva Pharmaceutical Industries	$1.01	2.86%	N/A	76.02%	N/A
VTRS Viatris	$0.48	2.95%	N/A	N/A	N/A
VTRS Viatris	$0.48	2.95%	N/A	N/A	N/A

Latest TEVA, VTRS, PFE, AMGN, and VTRS Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/4/2026	VTRS Viatris	quarterly	$0.12	2.88%	5/22/2026	5/22/2026	6/17/2026
5/4/2026	VTRS Viatris	quarterly	$0.12	2.88%	5/22/2026	5/22/2026	6/17/2026
4/22/2026	PFE Pfizer	quarterly	$0.43	6.71%	5/8/2026	5/8/2026	6/12/2026
3/4/2026	AMGN Amgen	quarterly	$2.52	3.09%	5/15/2026	5/15/2026	6/5/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMGN Amgen	5.65	1.26	1.01
PFE Pfizer	0.67	1.25	0.94
TEVA Teva Pharmaceutical Industries	1.70	1.01	0.78
VTRS Viatris	0.85	1.60	1.03
VTRS Viatris	0.85	1.60	1.03

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMGN Amgen	76.50%
PFE Pfizer	68.36%
TEVA Teva Pharmaceutical Industries	54.05%
VTRS Viatris	79.88%
VTRS Viatris	79.88%

Insider Ownership

Company	Insider Ownership
AMGN Amgen	0.85%
PFE Pfizer	0.62%
TEVA Teva Pharmaceutical Industries	0.54%
VTRS Viatris	0.28%
VTRS Viatris	0.28%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMGN Amgen	31,500	539.71 million	535.12 million	Optionable
PFE Pfizer	75,000	5.70 billion	5.66 billion	Optionable
TEVA Teva Pharmaceutical Industries	33,950	1.15 billion	1.14 billion	Optionable
VTRS Viatris	30,000	1.16 billion	1.16 billion	Optionable
VTRS Viatris	30,000	1.16 billion	1.16 billion	Optionable

TEVA, VTRS, PFE, AMGN, and VTRS Headlines

Recent News About These Companies

Assessing Viatris (VTRS) Valuation After FDA Review Acceptance For Fast Acting Non Opioid Meloxicam

May 24, 2026 | finance.yahoo.com

Barclays Remains a Buy on Viatris (VTRS)

May 21, 2026 | theglobeandmail.com

Viatris (VTRS): Buy, sell, or hold post Q1 earnings?

May 20, 2026 | msn.com

FDA Accepts Viatris' NDA for Fast-Acting Non-Opioid Pain Therapy

May 19, 2026 | zacks.com

Here's Why Viatris (VTRS) is a Strong Momentum Stock

May 18, 2026 | zacks.com

U.S. FDA Accepts Viatris New Drug Application for Fast-Acting Meloxicam for the Treatment of Moderate-to-Severe Acute Pain

May 18, 2026 | prnewswire.com

Deadline Alert: Viatris Inc. (VTRS) Investors Who Lost Money Urged to Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit

May 17, 2026 | businesswire.com

Does Strong Q1 Results And CFO Transition Change The Bull Case For Viatris (VTRS)?

May 17, 2026 | finance.yahoo.com

Viatris Shareholders Approve Directors, Pay and Auditor

May 15, 2026 | tipranks.com

Viatris (VTRS) price target increased by 10.47% to 17.48

May 14, 2026 | msn.com

Why Viatris (VTRS) is a top value stock for the long term

May 13, 2026 | msn.com

Why Viatris (VTRS) is a Top Value Stock for the Long-Term

May 13, 2026 | zacks.com

Viatris Inc. (VTRS) Presents at Bank of America Global Healthcare Conference 2026 Transcript

May 12, 2026 | seekingalpha.com

Why Viatris (VTRS) is a Top Growth Stock for the Long-Term

May 12, 2026 | zacks.com

Viatris: From Cost Story To Pipeline-Driven Re-Rating (Rating Upgrade)

May 12, 2026 | seekingalpha.com

Viatris Inc. stock falls Monday, underperforms market

May 11, 2026 | marketwatch.com

Viatris: The Cigar Butt Got Smoked, But I'm Holding The Rating

May 11, 2026 | seekingalpha.com

Most healthcare companies report higher Y/Y EPS in strong earnings week

May 11, 2026 | seekingalpha.com

Tracking Christopher Davis' Davis Selected Advisers 13F Portfolio - Q1 2026 Update

May 8, 2026 | seekingalpha.com

VTRS Q1 deep dive: China strength, R&D pipeline, and execution drive outperformance

May 8, 2026 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TEVA, VTRS, PFE, AMGN, and VTRS Company Descriptions

Amgen NASDAQ:AMGN

$336.79 +0.31 (+0.09%)

Closing price 04:00 PM Eastern

Extended Trading

$336.71 -0.08 (-0.02%)

As of 07:17 PM Eastern

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Pfizer NYSE:PFE

$26.18 +0.04 (+0.16%)

Closing price 03:59 PM Eastern

Extended Trading

$26.15 -0.03 (-0.13%)

As of 07:59 PM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Teva Pharmaceutical Industries NYSE:TEVA

$35.32 +0.80 (+2.33%)

Closing price 03:59 PM Eastern

Extended Trading

$35.09 -0.23 (-0.66%)

As of 07:47 PM Eastern

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

Viatris NASDAQ:VTRS

$16.26 +0.15 (+0.93%)

Closing price 04:00 PM Eastern

Extended Trading

$16.18 -0.09 (-0.52%)

As of 07:42 PM Eastern

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides it medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as glargine and SEMGLEE names. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; and Momenta Pharmaceuticals, Inc. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

Viatris NASDAQ:VTRS

$16.26 +0.15 (+0.93%)

Closing price 04:00 PM Eastern

Extended Trading

$16.18 -0.09 (-0.52%)

As of 07:42 PM Eastern

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TEVA, VTRS, PFE, AMGN, and VTRS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TEVA, VTRS, PFE, AMGN, and VTRS Earnings

Compare Dividends

Latest TEVA, VTRS, PFE, AMGN, and VTRS Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TEVA, VTRS, PFE, AMGN, and VTRS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TEVA, VTRS, PFE, AMGN, and VTRS Company Descriptions

Amgen NASDAQ:AMGN

Pfizer NYSE:PFE

Teva Pharmaceutical Industries NYSE:TEVA

Viatris NASDAQ:VTRS

Viatris NASDAQ:VTRS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools